Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056225 · ClinicalTrials.gov registry record · Phase 3
VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)
A Phase 3 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 3
- Development phase
- 340
- Enrollment target
NCT00056225 is a Phase 3 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 340 participants.
The verdict
NCT00056225, a Phase 3 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 340 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether reduction of homocysteine levels with high-dose folate (folic acid), B6, and B12 supplementation will slow the rate of cognitive decline in persons with Alzheimer's disease.
Interventions
- DRUG Vitamin B12
- DRUG Folate
- DRUG Vitamin B6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2003-01 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056225
The ClinicalTrials.gov registry entry for NCT00056225 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vitamin B12 is the first listed.
NCT00056225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056225 about?
NCT00056225 is a clinical study titled "VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)". The purpose of this study is to determine whether reduction of homocysteine levels with high-dose folate (folic acid), B6, and B12 supplementation will slow the rate of cognitive decline in persons with Alzheimer's disease.
What is the current status of trial NCT00056225?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 340 participants. The study started on 2003-01. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00056225?
The interventions under investigation include: Vitamin B12 (DRUG), Folate (DRUG), Vitamin B6 (DRUG).
Who is sponsoring clinical trial NCT00056225?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.